CareDx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CareDx, Inc. (CDNA) on January 21, 2021, reporting events occurring on January 20, 2021. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 1,923,077 shares of Common Stock.
- Public Offering Price: $91.00 per share.
- Underwriter Purchase Price: $85.54 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to 288,461 additional shares within 30 days.
- Expected Net Proceeds: Approximately $164.0 million (excluding the over-allotment option), after deducting underwriting discounts, commissions, and estimated expenses.
- Expected Closing Date: On or about January 25, 2021.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with Goldman Sachs & Co. LLC and Jefferies LLC as joint book-running managers. The offering is being made pursuant to a registration statement on Form S-3ASR filed on June 9, 2020. Additionally, the Company's directors and executive officers have entered into lock-up agreements prohibiting the sale or transfer of securities until March 21, 2021, with limited exceptions for Rule 10b5-1 trading plans.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the anticipated closing of the offering and expected proceeds. These statements are subject to risks and uncertainties, including the Company's ability to satisfy closing conditions, market conditions, and other risks detailed in periodic reports. The closing is contingent upon the satisfaction of customary conditions. The filing does not provide specific revenue, profit, or cash flow metrics for the reporting period, as it focuses solely on the capital raise transaction.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds received, as the $164.0 million figure is an estimate excluding the over-allotment option.
- Confirm whether the underwriters exercised the option to purchase the additional 288,461 shares.
- Review the Company's most recent periodic reports (10-K or 10-Q) for current liquidity, debt levels, and operating results, as this 8-K does not contain those figures.
- Monitor compliance with the lock-up agreement expiration on March 21, 2021, for potential selling pressure from insiders.